Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526704 | 0.85 | MAPT (0.56) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4534294 | 0.80 | ADAM17 (0.66) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4532011 | 0.80 | MAPT (0.60) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4538140 | 0.80 | LMNA (0.57) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2844427 | 0.74 | PPARA (0.62) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4536717 | 0.73 | LMNA (0.50) | MAPTLMNAALDH1A1NPSR1KMT2A | |
| SCHEMBL4541448 | 0.71 | ALDH1A1 (0.49) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL11550002 | 0.71 | ALDH1A1 (0.45) | MAPTLMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4536066 | 0.70 | LMNA (0.48) | MAPTLMNAALDH1A1NPSR1KMT2A | |
| SCHEMBL11828506 | 0.70 | HSD17B10 (0.51) | MAPTALDH1A1NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | MAPT 1533/4885LMNA 424/4885ALDH1A1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.